
Alkermes (ALKS) Stock Forecast & Price Target
Alkermes (ALKS) Analyst Ratings
Bulls say
Alkermes PLC demonstrated strong financial performance in 4Q24, with consolidated non-GAAP diluted EPS rising to $1.05, a substantial increase from $0.22 in the prior year’s quarter. The company reported total revenues of $430.0 million, reflecting a 13.9% year-over-year growth from $377.5 million, and net sales of proprietary products surged to $307.7 million, exceeding expectations significantly. Additionally, Alkermes is capitalizing on successful Phase 2 clinical trial results for TAK-861, which indicates promising advancements in addressing unmet medical needs, further solidifying its growth trajectory.
Bears say
Alkermes PLC has faced a notable decline in its manufacturing and royalty revenues, dropping to $122.3 million in the fourth quarter of 2024 compared to $135.5 million the previous year, signaling potential issues in its revenue generation strategy. Management's guidance for 2025 indicates a significant reduction in expected EBITDA, forecasting approximately $200 million rather than the previously anticipated $450 million, reflecting deteriorating profitability metrics. Additionally, the impending expiration of royalty agreements and declining performance in the base business further suggest a challenging growth outlook, which has adversely affected the company's valuation projections and overall financial stability.
This aggregate rating is based on analysts' research of Alkermes and is not a guaranteed prediction by Public.com or investment advice.
Alkermes (ALKS) Analyst Forecast & Price Prediction
Start investing in Alkermes (ALKS)
Order type
Buy in
Order amount
Est. shares
0 shares